Ketoprofen in Preventing Lymphedema in Patients At High Risk After Undergoing Axillary Lymph Node Dissection
This randomized clinical trial studies ketoprofen in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. Ketoprofen may prevent lymphedema in patients undergoing axillary lymph node dissection.
Unspecified Adult Solid Tumor, Protocol Specific
Other: laboratory biomarker analysis
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients|
- Incidence of lymphedema and/or severity of lymphedema [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
|Study Start Date:||December 2012|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Experimental: Arm I (ketoprofen)
Patients receive ketoprofen PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
Other Names:Other: laboratory biomarker analysis
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
Other Name: PLCBOther: laboratory biomarker analysis
I. To evaluate the efficacy of ketoprofen in improving chronic lymphedema while further elucidating the role of inflammatory and lymph angiogenic processes in the pathogenesis of this disease.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive ketoprofen orally (PO) thrice daily (TID) for up to 1 year in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 5 years.
|United States, California|
|Stanford University Hospitals and Clinics||Not yet recruiting|
|Stanford, California, United States, 94305|
|Contact: Stanley Rockson 650-498-7061 email@example.com|
|Principal Investigator: Stanley Rockson|
|Principal Investigator:||Stanley Rockson||Stanford University Hospitals and Clinics|